Tarsus Pharmaceuticals, Inc. (TARS)
收市後：
| 前收市價 | 26.41 |
| 開市 | 26.59 |
| 買盤 | 26.03 x 400 |
| 賣出價 | 26.18 x 400 |
| 今日波幅 | 25.72 - 26.79 |
| 52 週波幅 | 12.57 - 42.50 |
| 成交量 | |
| 平均成交量 | 581,237 |
| 市值 | 985.347M |
| Beta 值 (5 年，每月) | 1.10 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.75 |
| 業績公佈日 | 2024年8月08日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 57.38 |
Insider MonkeyTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript May 8, 2024 Tarsus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Tarsus’s First Quarter 2024 Financial Results Conference Call. As a reminder, this […]
ZacksTarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksDoes Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
